Teduglutide
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Teduglutide |
| DrugBank ID | DB08900 |
| Brand Names (EU) | Revestive |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.08% |
Approved Indication (EMA)
Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery. Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome. Patients should be stable following a period of intestinal adaptation after surgery.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | short bowel syndrome | 99.08% | DL |
| 2 | papillary conjunctivitis | 98.53% | DL |
| 3 | gastroduodenitis | 98.22% | DL |
| 4 | peptic ulcer disease | 96.58% | DL |
| 5 | nasal cavity disease | 96.22% | DL |
| 6 | acute laryngopharyngitis | 95.22% | DL |
| 7 | allergic urticaria | 95.17% | DL |
| 8 | pharyngitis | 94.68% | DL |
| 9 | chronic intestinal vascular insufficiency | 92.22% | DL |
| 10 | isolated mesenteric vein thrombosis | 91.99% | DL |
| 11 | atopic conjunctivitis | 88.73% | DL |
| 12 | cold urticaria | 87.89% | DL |
| 13 | rosacea conjunctivitis | 87.48% | DL |
| 14 | ischemic bowel disease | 87.48% | DL |
| 15 | NK-cell enteropathy | 86.49% | DL |
| 16 | eosinophilic gastrointestinal disease | 86.46% | DL |
| 17 | intestinal atresia (disease) | 86.43% | DL |
| 18 | solitary rectal ulcer syndrome | 86.30% | DL |
| 19 | neurogenic bowel | 86.30% | DL |
| 20 | mucocele of appendix | 86.30% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.